Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Beijing Double-Crane Buys Transfusion Maker Huali

publication date: Dec 23, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Beijing Double-Crane Pharma announced a small acquisition, saying it will pay 110 million RMB ($17.4 million) to buy Henan Shuanghe Huali Pharma. The purchase will increase Double-Crane’s market share in transfusion products. Huali makes large volume injections, granular formulations and hard capsules. More details....

Stock Symbol: (SHA: 600062)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...